

Jaishri O Blakeley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2897413/publications.pdf>

Version: 2024-02-01

133
papers

6,212
citations

81900

39
h-index

76900

74
g-index

139
all docs

139
docs citations

139
times ranked

6899
citing authors

#	ARTICLE	IF	CITATIONS
1	Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. <i>Nature Medicine</i> , 2011, 17, 130-134.	30.7	448
2	Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2020, 382, 1430-1442.	27.0	360
3	Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. <i>Magnetic Resonance in Medicine</i> , 2008, 60, 842-849.	3.0	304
4	Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. <i>Genetics in Medicine</i> , 2021, 23, 1506-1513.	2.4	290
5	Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. <i>Nature Genetics</i> , 2014, 46, 182-187.	21.4	242
6	First-in-Human Dose Study of the Novel Transforming Growth Factor- β 2 Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	7.0	199
7	Quantitative description of the asymmetry in magnetization transfer effects around the water resonance in the human brain. <i>Magnetic Resonance in Medicine</i> , 2007, 58, 786-793.	3.0	196
8	Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 1119-1128.	3.4	181
9	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. <i>American Journal of Human Genetics</i> , 2018, 102, 69-87.	6.2	144
10	Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 456-462.	3.4	132
11	Tissue concentration of systemically administered antineoplastic agents in human brain tumors. <i>Journal of Neuro-Oncology</i> , 2011, 104, 629-638.	2.9	122
12	High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. <i>Neurology</i> , 2014, 83, 235-239.	1.1	120
13	The Diagnosis and Management of Neurofibromatosis Type 1. <i>Medical Clinics of North America</i> , 2019, 103, 1035-1054.	2.5	116
14	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019, 21, 26-36.	1.2	114
15	Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. <i>Journal of Neuro-Oncology</i> , 2009, 91, 51-58.	2.9	112
16	Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. <i>Clinical Cancer Research</i> , 2019, 25, 552-561.	7.0	104
17	Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. <i>American Journal of Medical Genetics, Part A</i> , 2012, 158A, 24-41.	1.2	101
18	Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. <i>Neuro-Oncology</i> , 2016, 18, 624-638.	1.2	94

#	ARTICLE	IF	CITATIONS
19	Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2â€“Associated Vestibular Schwannomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 1669-1675.	1.6	92
20	Management of pineal region tumors. <i>Current Treatment Options in Oncology</i> , 2006, 7, 505-516.	3.0	85
21	Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas. <i>European Journal of Cancer</i> , 2017, 83, 9-18.	2.8	82
22	Cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S5-S13.	1.1	79
23	Review and consensus recommendations on clinical ^{3T}APT-weighted imaging approaches at ^{3T}: Application to brain tumors. <i>Magnetic Resonance in Medicine</i> , 2022, 88, 546-574.	3.0	79
24	Optimizing biologically targeted clinical trials for neurofibromatosis. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 443-462.	4.1	77
25	Drug delivery to brain tumors. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 235-241.	4.2	75
26	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. <i>Clinical Cancer Research</i> , 2009, 15, 5032-5039.	7.0	74
27	Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3446-3454.	1.6	73
28	Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. <i>Skeletal Radiology</i> , 2020, 49, 199-219.	2.0	69
29	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 403-426.	1.6	67
30	Current whole-body MRI applications in the neurofibromatoses. <i>Neurology</i> , 2016, 87, S31-9.	1.1	65
31	An update on the central nervous system manifestations of neurofibromatosis type 1. <i>Acta Neuropathologica</i> , 2020, 139, 625-641.	7.7	64
32	Achieving consensus for clinical trials. <i>Neurology</i> , 2013, 81, S1-5.	1.1	59
33	Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. <i>Neuro-Oncology</i> , 2020, 22, 912-917.	1.2	59
34	Thrombolytic therapy for acute ischemic stroke. <i>Journal of the Neurological Sciences</i> , 2007, 261, 55-62.	0.6	57
35	¹⁸F-FDG PET/CT Qualitative and Quantitative Evaluation in Neurofibromatosis Type 1 Patients for Detection of Malignant Transformation: Comparison of Early to Delayed Imaging With and Without Liver Activity Normalization. <i>Journal of Nuclear Medicine</i> , 2015, 56, 379-385.	5.0	54
36	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2021, 39, 797-806.	1.6	54

#	ARTICLE	IF	CITATIONS
37	Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. <i>Journal of Neuro-Oncology</i> , 2009, 93, 61-77.	2.9	48
38	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	30.7	46
39	Histopathological correlates with survival in reoperated glioblastomas. <i>Journal of Neuro-Oncology</i> , 2013, 113, 485-493.	2.9	44
40	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784.	1.2	44
41	Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors. <i>Neuro-Oncology Practice</i> , 2015, 2, 127-136.	1.6	41
42	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2018, 20, 897-906.	1.2	41
43	glucose weighted chemical exchange saturation transfer (glucoCEST)-based dynamic glucose enhanced (DGE) MRI at 3T: early experience in healthy volunteers and brain tumor patients. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 247-262.	3.0	41
44	Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. <i>Neuro-Oncology</i> , 2020, 22, 1368-1378.	1.2	37
45	Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1477-1491.	3.3	36
46	Clinical response to bevacizumab in schwannomatosis. <i>Neurology</i> , 2014, 83, 1986-1987.	1.1	33
47	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology</i> , The, 2018, 19, e173-e180.	10.7	32
48	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. <i>Neuro-Oncology</i> , 2022, 24, 1845-1856.	1.2	30
49	Management of neurofibromatosis type 1-associated plexiform neurofibromas. <i>Neuro-Oncology</i> , 2022, 24, 1827-1844.	1.2	29
50	Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. <i>Neuro-Oncology</i> , 2016, 18, ii13-ii20.	1.2	27
51	Radiation-Induced Myelitis: Initial and Follow-Up MRI and Clinical Features in Patients at a Single Tertiary Care Institution during 20 Years. <i>American Journal of Neuroradiology</i> , 2018, 39, 1576-1581.	2.4	27
52	The biology of cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S14-S20.	1.1	27
53	Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. <i>Acta Neuropathologica</i> , 2021, 141, 101-116.	7.7	26
54	Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. <i>Journal of Neuro-Oncology</i> , 2014, 116, 59-65.	2.9	24

#	ARTICLE	IF	CITATIONS
55	Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis. <i>ISRN Radiology</i> , 2013, 2013, 1-9.	1.2	24
56	Schwannoma in neurofibromatosis type 1: a pitfall for detecting malignancy by metabolic imaging. <i>Skeletal Radiology</i> , 2013, 42, 1317-1322.	2.0	23
57	Current status and recommendations for biomarkers and biobanking in neurofibromatosis. <i>Neurology</i> , 2016, 87, S40-8.	1.1	23
58	Considerations for development of therapies for cutaneous neurofibroma. <i>Neurology</i> , 2018, 91, S21-S30.	1.1	23
59	Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 794-803.	3.4	22
60	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2016, 18, ii26-ii36.	1.2	22
61	Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 19-27.	2.8	22
62	EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. <i>Neuro-Oncology</i> , 2018, 20, 1185-1196.	1.2	22
63	Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2012, 20, 372-379.	1.8	21
64	Clinical Management of Seizures in Patients With Low-Grade Glioma. <i>Seminars in Radiation Oncology</i> , 2015, 25, 219-224.	2.2	21
65	Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. <i>Scientific Data</i> , 2018, 5, 180106.	5.3	20
66	Anaplastic oligodendroglioma. <i>Current Treatment Options in Neurology</i> , 2008, 10, 295-307.	1.8	19
67	A clinically and genomically annotated nerve sheath tumor biospecimen repository. <i>Scientific Data</i> , 2020, 7, 184.	5.3	19
68	Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. <i>PLoS ONE</i> , 2021, 16, e0252048.	2.5	19
69	The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 397-408.	4.1	18
70	Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma. <i>Neurology</i> , 2021, 97, e953-e963.	1.1	18
71	Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. <i>PLoS ONE</i> , 2018, 13, e0197350.	2.5	17
72	Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 1455-1461.	1.2	16

#	ARTICLE	IF	CITATIONS
73	Moyamoya disease versus moyamoya syndrome: comparison of presentation and outcome in 338 hemispheres. <i>Journal of Neurosurgery</i> , 2020, 133, 1441-1449.	1.6	16
74	Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 93-100.	2.3	15
75	Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1. <i>Neurology</i> , 2016, 87, S13-20.	1.1	15
76	Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. <i>Otology and Neurotology</i> , 2018, 39, 632-638.	1.3	15
77	Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the <i>NF2</i> gene. <i>Laryngoscope</i> , 2019, 129, 967-973.	2.0	15
78	The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 129-139.	2.3	14
79	NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i143-i143.	1.2	14
80	Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. <i>Neuro-Oncology</i> , 2022, 24, 1978-1988.	1.2	14
81	Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa154.	0.7	13
82	Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 73-79.	7.0	12
83	Telomere alterations in neurofibromatosis type 1-associated solid tumors. <i>Acta Neuropathologica Communications</i> , 2019, 7, 139.	5.2	12
84	Effect of ketogenic diets on leukocyte counts in patients with epilepsy. <i>Nutritional Neuroscience</i> , 2019, 22, 522-527.	3.1	12
85	Creating a comprehensive research strategy for cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S1-S4.	1.1	11
86	Clinical trial design for cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S31-S37.	1.1	11
87	Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1. <i>Genes</i> , 2020, 11, 226.	2.4	11
88	Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1584-1591.	4.1	11
89	Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients. <i>PLoS ONE</i> , 2015, 10, e0144620.	2.5	10
90	The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma. <i>Journal of Neuro-Oncology</i> , 2017, 135, 47-56.	2.9	10

#	ARTICLE	IF	CITATIONS
91	Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of <i>Nf1</i> -Deficient Mice. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2321-2330.	4.1	10
92	Chemotherapy with cytotoxic and cytostatic agents in brain cancer. <i>Handbook of Clinical Neurology</i> / Edited By PJ Vinken and G W Bruyn, 2012, 104, 229-254.	1.8	9
93	Voice and Swallowing Dysfunction in Neurofibromatosis 2. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 505-510.	1.9	9
94	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021, 8, 417-425.	1.6	9
95	NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM. <i>Neuro-Oncology</i> , 2020, 22, iii420-iii421.	1.2	9
96	Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 125, 123-131.	2.9	8
97	Cutaneous manifestations in neuro-oncology: clinically relevant tumor and treatment associated dermatologic findings. <i>Seminars in Oncology</i> , 2016, 43, 401-407.	2.2	8
98	Engaging a community to enable disease-centric data sharing with the NF Data Portal. <i>Scientific Data</i> , 2019, 6, 319.	5.3	8
99	Association between patient-reported outcomes and objective disease indices in people with NF2. <i>Neurology: Clinical Practice</i> , 2019, 9, 322-329.	1.6	7
100	Complete Radiologic Response and Long-Term Survival With Use of Systemic High-Dose Methotrexate for Breast Cancer—Associated Leptomeningeal Disease. <i>Clinical Breast Cancer</i> , 2012, 12, 445-449.	2.4	6
101	Low-grade Schwann cell neoplasms with leptomeningeal dissemination: clinicopathologic and autopsy findings. <i>Human Pathology</i> , 2017, 60, 121-128.	2.0	6
102	Cerebral Ketones Detected by 3T MR Spectroscopy in Patients with High-Grade Glioma on an Atkins-Based Diet. <i>American Journal of Neuroradiology</i> , 2019, 40, 1908-1915.	2.4	6
103	Validating Techniques for Measurement of Cutaneous Neurofibromas. <i>Neurology</i> , 2021, 97, S32-S41.	1.1	6
104	Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Neurology</i> , 2021, 97, S111-S119.	1.1	6
105	Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas. <i>Neurology</i> , 2021, 97, S15-S24.	1.1	5
106	Clinical Reasoning: Multiple cranial neuropathies in a young man. <i>Neurology</i> , 2013, 80, e60-6.	1.1	4
107	How Critical Is the Blood-Brain Barrier to the Development of Neurotherapeutics?. <i>JAMA Neurology</i> , 2015, 72, 381.	9.0	4
108	Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 Neurofibromatosis. <i>World Neurosurgery</i> , 2017, 99, 19-25.	1.3	4

#	ARTICLE	IF	CITATIONS
109	Germline and Somatic <i>NF1</i> Alterations Are Linked to Increased HER2 Expression in Breast Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 655-664.	1.5	4
110	Brain Cancers in Genetic Syndromes. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 64.	4.2	4
111	Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma. <i>ELife</i> , 2022, 11, .	6.0	4
112	Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 2672-2683.	1.2	4
113	Learning-based analysis of amide proton transfer-weighted MRI to identify true progression in glioma patients. <i>NeuroImage: Clinical</i> , 2022, , 103121.	2.7	4
114	Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromas. <i>Neuro-Oncology Advances</i> , 2020, 2, i117-i123.	0.7	3
115	The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1530.	1.2	3
116	Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28372.	1.5	3
117	RARE-54. MEK INHIBITION FOR AGGRESSIVE GLIOMAS IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1. <i>Neuro-Oncology</i> , 2019, 21, vi233-vi233.	1.2	2
118	QOLP-20. IMPACT OF GLIOBLASTOMA ON PATIENT-REPORTED SYMPTOM BURDEN AND PHYSICAL ACTIVITY ASSESSED BY CONVENTIONAL INSTRUMENTS AND A NOVEL DEVICE-BASED TECHNOLOGY. <i>Neuro-Oncology</i> , 2019, 21, vi201-vi202.	1.2	2
119	Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. <i>Neurology</i> , 2021, 97, S99-S110.	1.1	2
120	Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research. <i>Neurology</i> , 2021, 97, S42-S49.	1.1	2
121	Pineal Region Tumors. , 2011, , 435-455.		2
122	Case 5: altered mental status and fever after resection of glioblastoma multiforme. <i>MedGenMed: Medscape General Medicine</i> , 2004, 6, 49.	0.2	2
123	A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1246-1258.	4.1	2
124	Neoplastic and Paraneoplastic Disorders. , 2009, , 233-247.		1
125	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Neuro-Oncology</i> , 2022, 24, 358-383.	1.2	1
126	NFM-09. PRELIMINARY REPORT OF A MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i144-i144.	1.2	0

#	ARTICLE	IF	CITATIONS
127	RARE-15. OUTCOMES OF TREATMENT OF GLIOMAS IN PATIENTS WITH NEUROFIBROMATOSIS TYPE I TREATED WITH RADIATION THERAPY. <i>Neuro-Oncology</i> , 2019, 21, vi224-vi224.	1.2	0
128	ACTR-44. FEASIBILITY, PHARMACODYNAMICS, AND BIOLOGIC ACTIVITY OF THE GLIOMA ATKINS-BASED DIET (GLAD) FOR PREVENTING TUMOR RECURRENCE IN GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi23-vi23.	1.2	0
129	DDIS-21. IN VITRO MICRODIALYSIS RECOVERY OF TRAMETINIB. <i>Neuro-Oncology</i> , 2019, 21, vi67-vi67.	1.2	0
130	ACTR-09. A PHASE 0 PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF EVEROLIMUS IN VESTIBULAR SCHWANNOMA (VS) AND MENINGIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi14-vi14.	1.2	0
131	QOLP-31. ASSESSING THE IMPACT OF GLIOBLASTOMA ON WORK PRODUCTIVITY IN PATIENTS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2019, 21, vi204-vi204.	1.2	0
132	DDRE-31. FEASIBILITY AND BIOLOGIC ACTIVITY OF A KETOGENIC / INTERMITTENT FASTING DIET IN GLIOMA PATIENTS. <i>Neuro-Oncology Advances</i> , 2021, 3, i13-i13.	0.7	0
133	Approach to patients with the neoplasms associated with neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. , 2021, , 210-228.		0